Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Short term Debt (2022 - 2024)

Inmune Bio (INMB) has disclosed Short term Debt for 3 consecutive years, with $2.5 million as the latest value for Q3 2024.

  • Quarterly Short term Debt fell 75.06% to $2.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Sep 2024, down 75.06% year-over-year, with the annual reading at $9.9 million for FY2023, 98.42% up from the prior year.
  • Short term Debt hit $2.5 million in Q3 2024 for Inmune Bio, down from $5.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $10.0 million in Q2 2023 to a low of $2.5 million in Q3 2024.
  • Historically, Short term Debt has averaged $6.6 million across 3 years, with a median of $7.5 million in 2024.
  • Biggest five-year swings in Short term Debt: soared 300.0% in 2023 and later crashed 75.06% in 2024.
  • Year by year, Short term Debt stood at $5.0 million in 2022, then surged by 98.42% to $9.9 million in 2023, then crashed by 74.86% to $2.5 million in 2024.
  • Business Quant data shows Short term Debt for INMB at $2.5 million in Q3 2024, $5.0 million in Q2 2024, and $7.5 million in Q1 2024.